Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1989 3
1990 2
1991 2
1992 2
1993 6
1994 4
1995 2
1996 1
1997 3
1998 2
1999 3
2000 2
2001 1
2002 4
2003 5
2004 3
2005 2
2007 1
2008 1
2009 3
2010 6
2011 3
2012 2
2013 2
2014 4
2015 3
2017 4
2018 4
2019 4
2020 2
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

87 results
Results by year
Filters applied: . Clear all
Page 1
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Woo XY, et al. Among authors: moscow ja. Nat Genet. 2021 Jan;53(1):86-99. doi: 10.1038/s41588-020-00750-6. Epub 2021 Jan 7. Nat Genet. 2021. PMID: 33414553 Free PMC article.
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, Lau CL, Sholl L, Takebe N, Moscow JA, Shapiro GI, Jänne PA, Oxnard GR. Bertino EM, et al. Among authors: moscow ja. Clin Cancer Res. 2021 Mar 15;27(6):1604-1611. doi: 10.1158/1078-0432.CCR-20-4084. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376097 Free PMC article.
The evidence framework for precision cancer medicine.
Moscow JA, Fojo T, Schilsky RL. Moscow JA, et al. Nat Rev Clin Oncol. 2018 Mar;15(3):183-192. doi: 10.1038/nrclinonc.2017.186. Epub 2017 Dec 19. Nat Rev Clin Oncol. 2018. PMID: 29255239 Review.
Multidrug resistance.
Moscow JA, Cowan KH. Moscow JA, et al. J Natl Cancer Inst. 1988 Mar 2;80(1):14-20. doi: 10.1093/jnci/80.1.14. J Natl Cancer Inst. 1988. PMID: 2892943 Review.
Methotrexate transport and resistance.
Moscow JA. Moscow JA. Leuk Lymphoma. 1998 Jul;30(3-4):215-24. doi: 10.3109/10428199809057535. Leuk Lymphoma. 1998. PMID: 9713954 Review.
Steps forward for cancer precision medicine.
Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty. Salgado R, et al. Among authors: moscow ja. Nat Rev Drug Discov. 2018 Jan;17(1):1-2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24. Nat Rev Drug Discov. 2018. PMID: 29170471
Multidrug resistance.
Moscow JA, Schneider E, Cowan KH. Moscow JA, et al. Cancer Chemother Biol Response Modif. 1996;16:111-31. Cancer Chemother Biol Response Modif. 1996. PMID: 8639380 Review. No abstract available.
Multidrug resistance.
Moscow JA, Schneider E, Cowan KH. Moscow JA, et al. Cancer Chemother Biol Response Modif. 1994;15:99-129. Cancer Chemother Biol Response Modif. 1994. PMID: 7779609 Review. No abstract available.
Multidrug resistance.
Moscow JA, Morrow CS, Cowan KH. Moscow JA, et al. Cancer Chemother Biol Response Modif. 1992;13:91-114. Cancer Chemother Biol Response Modif. 1992. PMID: 1356403 Review. No abstract available.
87 results